ArticleScientific reports2026
Eco-optimized RP-HPLC method for chiral tazobactam and piperacillin drugs: integration with Box-Behnken design and multi-sustainability tools.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piperacillin-tazobactam (PIP-TAZ) is an effective antimicrobial agent, indicated primarily for severe infections resulting from susceptible organisms, and it has undisputed importance within antimicrobial therapy. PIP-TAZ combinations are widely used to treat severe infections caused by Gram-negative and Gram-positive bacteria, including those that produce β-lactamases. Our study involved the development of an environmentally friendly RP-HPLC method for the simultaneous determination of TAZ and PIP. In lieu of conducting numerous experiments, an efficient method to achieve the three major parameters of chromatography-pH, flow rate, and column temperature-was optimized with the help of a Box-Behnken Design (BBD) to minimize variability. This approach streamlines the experimental process and enhances results reliability. By carefully controlling these parameters, researchers can achieve more consistent and reproducible chromatographic analyses. This research addresses the impact that these variables have on such critical responses as retention times for TAZ and PIP and their resolution. The identification of optimal conditions was based on desirable and overlay plots. The samples were dissolved in ethanol, water, and tetrabutylammonium hydroxide in the mobile phase and separated through chromatography (58.5:40:1.5, v/v/v), and the pH was maintained at 3.5 with phosphoric acid. The method used UV detection at 230 nm, an injection volume of 20 μL, and a column temperature of 30°C. It was run at a flow rate of 1.0 mL/min. It used a Symmetry Shield RP18 column for 100-micron pore size, 5-micron particle size, and 4.6-mm by 250-mm dimensions. A comparison of carbon footprint reduction index (CaFRI), analytical greenness (AGREE), analytical eco-scales, green analytical procedure index (GAPI), modified GAPI (MoGAPI), and analytical method volume intensity (AMVI), which authenticates the accuracy, precision, and robustness of the method, was made in conjunction with a lesser environmental impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.